If Dominissini validates Zan as an FTO inhibitor; the market opportunity goes from 'niche aml chemotherapeutic' to 'every cancer subset where fto expression is high and every cancer treatment that upregulates fto expression (almost all of them)'.
Holders would be better off digesting the magnitude of this potential revelation rather than concerning themselves with overseas listing's.
Industry news, page-967
-
- There are more pages in this discussion • 848 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
